Insmed (INSM) PT Raised to $230 at Cantor Fitzgerald Brenso Potential

Cantor Fitzgerald analyst Olivia Brayer raised the price target on Insmed (NASDAQ: INSM) to $230.00 (from $216.00) while maintaining a Overweight rating.

The analyst commented, "We think brenso has a good chance to show a benefit in CRSsNP (on top of a steroid nasal spray). We don't have any concrete data to back it up, but here's the basic point we're making: Adding brenso to intranasal steroids should have an additive/synergistic effect in CRSsNP patients, because brenso hits inflammatory pathways that steroids don't meaningfully control (particularly neutrophil-driven inflammation). Neutrophils are steroid "resistant," and brenso + steroids work from different angles on the immune system through complementary MOAs. We think this could translate into additive or even synergistic clinical effects."

You May Also Be Interested In

• Wolverine World Wide (WWW) PT Raised to $31 at UBS on Growth, EPS Upside Potential
• Aebi Schmidt Holding AG (AEBI) PT Raised to $17 at DA Davidson as Shares Remain Undervalued
• Regeneron Pharma (REGN) PT Raised to $756 at Bernstein SocGen Group